Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes

J Am Coll Cardiol. 2024 Aug 6;84(6):558-560. doi: 10.1016/j.jacc.2024.05.045.

Authors

Silvio E Inzucchi¹, Andrew E Arai²

Affiliations

¹ Section of Endocrinology and Metabolism, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: [email protected].
² Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.

PMID: 39084830
DOI: 10.1016/j.jacc.2024.05.045

No abstract available

Keywords: GLP-1 receptor agonists; NMR spectroscopy; cardiac magnetic resonance (CMR); cardiovascular disease; type 2 diabetes.

Publication types

Review
Editorial

MeSH terms

Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor Agonists*
Heart Disease Risk Factors
Humans
Hypoglycemic Agents* / therapeutic use

Substances

Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists